Drug Topics
NOVEMBER 27, 2023
A new study found that models that included wastewater data were 15% more accurate when compared to models that only included clinical case data.
Pharmacy Times
NOVEMBER 27, 2023
Pharmacies have the potential to introduce testing services, promote public health campaigns, collaborate with anemia-led clinics, and get more prescribing rights to diagnose anemia.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
NOVEMBER 27, 2023
Study findings offer critical insight into the development of sex-specific treatment and prevention strategies for Alzheimer’s disease.
Pharmacy Times
NOVEMBER 27, 2023
Although social determinants of health (SDOH) have been a major barrier to access of preexposure prophylaxis for those who are at risk of HIV, commercial determinants of health pose a similar barrier.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
NOVEMBER 27, 2023
About 20 million disabled people will be erased if the U.S. Census Bureau moves forward with changes to disability data collection methods. That is because many disabled people will no longer be counted as disabled by the new questions the Census is proposing to use starting in 2025 with the annual American Community Survey (ACS). As disabled people, and as scholars who study disability measurement and use disability data for our research, we have grave concerns about this proposed change.
Fierce Healthcare
NOVEMBER 27, 2023
Hospitals in multiple states have been forced to divert ambulances and reschedule some elective patient procedures after U.S. | Hospitals in multiple states have been forced to divert ambulances and reschedule some elective procedures after U.S. hospital owner Ardent Health Services was hit with a ransomware attack.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Healthcare
NOVEMBER 27, 2023
Mark Cuban Cost Plus Drug Company has inked its latest partnership, joining forces with Expion Health to address the rising cost of specialty drugs. | Mark Cuban Cost Plus Drug Company has inked its latest partnership, joining forces with Expion Health to address the rising cost of specialty drugs.
STAT
NOVEMBER 27, 2023
After earning her doctorate in cell biology at the University of Pennsylvania in June, Sierra Collins did what many freshly minted Ph.D.s. do — she went looking for a job at a biotech company. But what was supposed to be a straightforward search has turned into an odyssey. Collins has applied for more than 53 positions (and counting). Like a good scientist, she’s gathering data along the way and uses a spreadsheet to track each company’s size and therapeutic focus, as well a
Fierce Pharma
NOVEMBER 27, 2023
Following the historic approval of the world’s first CRISPR-based gene-editing therapy in the United Kingdom this month, Vertex Pharmaceuticals has tapped its long-time manufacturing partner Roslin | RoslinCT, the CDMO arm of the Roslin Institute, is set to manufacture Vertex and CRISPR Therapeutics’ exa-cel “across the world” as part of Vertex’s global production network.
The Checkup by Singlecare
NOVEMBER 27, 2023
Strep throat is one of the most common reasons for a sore throat. About 5% to 15% of sore throats in adults and 20% to 30% of sore throats in kids are caused by a strep infection, which is caused by group A streptococcus bacteria. If you or your child has strep throat, you may rush to the doctor to request an antibiotic—but do you actually need antibiotics to treat strep?
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Fierce Pharma
NOVEMBER 27, 2023
After plotting $6 billion in production upgrades earlier this month, Novo Nordisk’s CEO Lars Fruergaard Jørgensen suggested the expansion outlay was just the start. | After plotting $6 billion in production upgrades earlier this month, Novo Nordisk’s CEO Lars Fruergaard Jørgensen suggested the expansion outlay was just the start. Now, some three weeks later, he’s putting his company’s money where his mouth is.
Pharmacy Times
NOVEMBER 27, 2023
Study results indicate that outcomes were worse among those who inject illicit drugs and Black patients living with HIV.
Drug Topics
NOVEMBER 27, 2023
The NOTUS trial was shown to have successfully achieved its primary endpoint, demonstrating the notable efficacy of dupilumab in reducing exacerbations by 34% versus placebo in individuals with moderate-to-severe COPD showing evidence of type 2 inflammation.
Fierce Pharma
NOVEMBER 27, 2023
Eli Lilly’s fortunes have turned quickly. | It was the second straight quarter where the overwhelming success of blood sugar regulating treatments were the dominant story in the biopharma industry. Eli Lilly and Novo Nordisk delivered the highest revenue gains, at 38% and 29%, respectively.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
NOVEMBER 27, 2023
The study authors reported that plans in the South had the highest rates of exclusive PAs for either emtricitabine/tenofovir disoproxil fumarate or emtricitabine/tenofovir alafenamide even if the plan covered both, from 2018 to 2020.
STAT
NOVEMBER 27, 2023
The Food and Drug Administration on Monday approved the first treatment for people with desmoid tumors, a localized cancer that invades soft tissue and muscle. The new drug, called Ogsiveo, is made by Springworks Therapeutics. It’s the company’s first approved medicine. Desmoid tumors are fibrous growths that start in connective tissue and are often found in the abdomen, arms, legs, and torso.
Pharmacy Times
NOVEMBER 27, 2023
Major barriers to care for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) can include navigating therapeutics and the cost of medications.
STAT
NOVEMBER 27, 2023
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello! Hope you had a peaceful holiday. Back to biotech, we discuss the tough job market, delight in some exciting early developments in CAR-T and CRISPR, and see further validation for the blockbuster anti-inflammatory drug Dupixent.
Outsourcing Pharma
NOVEMBER 27, 2023
It is five years this month since a ground-breaking change in UK healthcare history happened â with doctors being able to prescribe cannabis-based medicines for the first time.
Drug Topics
NOVEMBER 27, 2023
Vaccinated study participants experienced fewer and less persistent symptoms, as well as fewer work hours lost, compared to unvaccinated participants.
STAT
NOVEMBER 27, 2023
Amid concerns over the use of medically important antibiotics given to food-producing livestock, sales of veterinary medicines across Europe dropped by 53% between 2011 and 2022, which regulators reported is the biggest drop ever recorded and a sign that campaigns to reduce usage are working. At issue is the extent to which antibiotics are given to these livestock to prevent and treat disease — a practice that has contributed to an alarming rise in antibiotic-resistant bacteria in humans.
pharmaphorum
NOVEMBER 27, 2023
EVERSANA’s alliance with Amazon Web Services (AWS) on the application of generative artificial intelligence (genAI) to the pharma sector has borne its first fruit – a new tool to tackle the time-consuming and error-prone task of getting medical and regulatory content approvals.
Fierce Healthcare
NOVEMBER 27, 2023
With their recent stability, the Affordable Care Act marketplaces are well-positioned for innovation—but there's still room to take what's working nationwide, according to a new report. | With their recent stability, the Affordable Care Act marketplaces are well-positioned for innovation — but there's still room to take what's working nationwide, according to a new report.
STAT
NOVEMBER 27, 2023
Just 3% of more than 3,700 studies run exclusively in Canada over a recent 10-year period were registered prospectively, reported results, and published the findings, underscoring ongoing concerns about clinical trial transparency, according to a new analysis. More specifically, 47% of those trials, or more than 1,770, were registered in advance, while only 12% reported results in a registry, and only 48% published their findings.
The FDA Law Blog
NOVEMBER 27, 2023
By Riëtte van Laack & Anne K. Walsh — Although the Consumer Product Safety Act (CPSA) has been around for over 50 years to “protect the public against unreasonable risks of injury associated with consumer products,” it was not until 2008 that the statute was amended to authorize the Consumer Product Safety Commission (“CPSC”) to impose criminal liability against individual directors, officers, or agents of a corporation for violating the CPSA.
Fierce Pharma
NOVEMBER 27, 2023
Is Blenrep back from the dead? After a positive trial readout, GSK sure hopes so. | Is Blenrep back from the dead? After a positive trial readout for the BCMA-targeted antibody-drug conjugate, GSK sure hopes so.
pharmaphorum
NOVEMBER 27, 2023
A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the drug may still have a role to play earlier on in the treatment pathway.
European Pharmaceutical Review
NOVEMBER 27, 2023
The National Institute for Health and Care Excellence (NICE) has recommended enzyme replacement therapy sebelipase alfa (Kanuma ® ▼) in final draft guidance. Alexion’s (AstraZeneca Rare Disease) intravenous treatment is recommended for children who have been diagnosed with Wolman Disease at two years old or younger. This ultra-rare metabolic disease occurs due to lysosomal acid lipase (LAL) enzyme deficiency.
STAT
NOVEMBER 27, 2023
Good morning, everyone, and nice to see you again after an extended break on this side of the pond. We hope your own respite was relaxing and invigorating, because that oh-so familiar routine of online calls and meetings and deadlines has predictably returned. But you knew this would happen, did you not? So time to fire up the coffee kettle and brew another cup of stimulation.
Drug Store News
NOVEMBER 27, 2023
The big five immunity ingredients are vitamins C and D, zinc, elderberry and probiotics. But other bioactives still vie for consumer acclaim.
Fierce Pharma
NOVEMBER 27, 2023
Sanofi and Regeneron’s Dupixent has scored in a second phase 3 study in chronic obstructive pulmonary disease (COPD), setting up the monoclonal antibody to become the first biologic to treat the lu | Sanofi and Regeneron’s Dupixent has scored in a second phase 3 study in chronic obstructive pulmonary disease (COPD), setting up the monoclonal antibody to become the first biologic to treat the lung disease and the first advancement in the indication in more than a decade.
Drug Store News
NOVEMBER 27, 2023
In connection with Mallinckrodt's emergence, David Stetson, executive chairman of Alpha Metallurgical Resources, and Jon Zinman, a managing director at Silver Point Capital, have been appointed to the board, effective immediately.
PharmaVoice
NOVEMBER 27, 2023
A drug developed by Kinnov Therapeutics halved alcohol consumption in heavy drinkers in a mid-stage study
Drug Store News
NOVEMBER 27, 2023
DSN is keeping an eye out for beauty brands set to make waves on physical and digital shelves.
Expert insights. Personalized for you.
201 
Let's personalize your content